^
Association details:
| Biomarker: | CTSS Y132D |
|---|---|
| Cancer: | Follicular Lymphoma |
| Regimen: | R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MUTATIONAL PROFILE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA AND CORRELATION WITH OUTCOME AFTER TREATMENT WITH INMUNOCHEMOTHERAPY
Published date:
06/12/2020
Excerpt:
we detected 6 cases presenting the hotspot mutation Y132D in the gene CTSS; ...this tyrosine to aspartic acid substitution in the peptidase C1 domain, that seems to be restricted to FL, showed in our series a trend to significant better outcome, with 10-y PFS of 82% in mutated cases...
